Surenano Science closes acquisition of GlucaPharm

Executive Summary

• Surenano Science Ltd. has completed the acquisition of GlucaPharm Inc., a pharmaceutical company developing GEP44, a second-generation GLP-1 therapeutic candidate for obesity and metabolic disease.
• The transaction is structured as a share exchange, with Surenano issuing 8,100,999 common shares and warrants to purchase 5 million common shares to GlucaPharm stakeholders.
• The acquisition accelerates Surenano’s transition into a pharmaceutical value creator, leveraging GlucaPharm’s patented asset which aims to provide improved tolerability and non-injectable delivery options compared to first-generation GLP-1 drugs.

Key Details

• Transaction Structure: Share exchange acquisition completed.
• Consideration:
  • 8,100,999 common shares of Surenano issued to GlucaPharm shareholders.
  • Warrants to purchase 5,000,000 common shares of Surenano issued to the holder of GlucaPharm warrants.
• Share Restrictions: Issued shares are subject to a hold period legend preventing sale, transfer, or trading until the later of:
  • Approval by the Canadian Securities Exchange of Surenano’s 2026 annual Form 5A.
  • Release of Surenano’s 2026 annual audited financial statements.
• Asset Details (GlucaPharm/GEP44):
  • GEP44 is a novel, patented peptide developed by Syracuse University researchers.
  • Preclinical studies show significant weight reduction and blood glucose normalization without the nausea/GI side effects common in first-generation GLP-1s (e.g., Ozempic, Wegovy).
  • Potential for non-injectable administration (oral, sublingual, or nasal).
  • Exclusively licensed from Syracuse University.
• Development Pipeline:
  • Collaboration with an Australian contract research organization (CRO).
  • IND-enabling FDA study followed by Phase I clinical trial expected to commence in Australia in the coming months.
  • Key milestones (IND progression, early clinical validation) anticipated over the next 6–9 months.
• Leadership Changes:
  • Dr. Nihar R. Pandey appointed as Director and Chief Scientific Officer.
  • Dr. Pandey holds a PhD in clinical biochemistry with over 25 years of experience in drug discovery, development, and regulatory compliance.
• Financial Context:
  • Surenano recently completed $1.25 million in financing (referenced from Dec. 10, 2025 release), including warrants exercisable at 35 cents, to support near-term development.

Notable Quotes

• "This acquisition marks a transformational milestone for Surenano. GlucaPharm provides the company with a highly differentiated GLP asset at a time when demand for effective, better-tolerated metabolic therapies continues to accelerate globally." — Charles MaLette, CEO, Surenano Science Ltd.